Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research note issued to investors on Tuesday. The firm currently has $117.64 target price on the stock.

A number of other analysts also recently commented on the company. Zacks Investment Research raised Johnson & Johnson from a hold rating to a buy rating and set a $139.00 price objective on the stock in a research note on Friday, August 5th. BTIG Research restated a neutral rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. RBC Capital Markets set a $133.00 target price on Johnson & Johnson and gave the stock a buy rating in a report on Wednesday, November 9th. Bank of America Corp. restated a hold rating and issued a $126.00 target price on shares of Johnson & Johnson in a report on Monday. Finally, Credit Suisse Group AG restated a neutral rating and issued a $123.00 target price on shares of Johnson & Johnson in a report on Monday, September 19th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $121.03.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) opened at 112.48 on Tuesday. The stock has a market capitalization of $306.01 billion, a P/E ratio of 19.74 and a beta of 0.75. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The company’s 50-day moving average price is $115.85 and its 200 day moving average price is $118.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The company had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. During the same quarter in the previous year, the business earned $1.49 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post $6.72 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Upgraded by Vetr Inc. to Buy” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/30/johnson-johnson-jnj-upgraded-by-vetr-inc-to-buy.html.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. This represents a $3.20 annualized dividend and a yield of 2.84%. Johnson & Johnson’s dividend payout ratio is currently 56.64%.

In other news, Director Charles Prince acquired 875 shares of Johnson & Johnson stock in a transaction on Friday, October 21st. The shares were purchased at an average price of $114.11 per share, with a total value of $99,846.25. Following the acquisition, the director now owns 26,520 shares in the company, valued at $3,026,197.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.11% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Canandaigua National Bank & Trust Co. increased its position in Johnson & Johnson by 0.3% in the first quarter. Canandaigua National Bank & Trust Co. now owns 97,516 shares of the company’s stock worth $10,551,000 after buying an additional 291 shares during the period. Royal Bank of Scotland Group PLC increased its position in Johnson & Johnson by 1.7% in the first quarter. Royal Bank of Scotland Group PLC now owns 10,950 shares of the company’s stock worth $1,184,000 after buying an additional 182 shares during the period. USS Investment Management Ltd increased its position in Johnson & Johnson by 38.9% in the first quarter. USS Investment Management Ltd now owns 211,814 shares of the company’s stock worth $22,913,000 after buying an additional 59,314 shares during the period. Shufro Rose & Co. LLC increased its position in Johnson & Johnson by 22.8% in the first quarter. Shufro Rose & Co. LLC now owns 50,889 shares of the company’s stock worth $5,506,000 after buying an additional 9,440 shares during the period. Finally, Bessemer Group Inc. increased its position in Johnson & Johnson by 77.1% in the first quarter. Bessemer Group Inc. now owns 748,552 shares of the company’s stock worth $80,994,000 after buying an additional 325,913 shares during the period. 64.13% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.